Objective: This study aimed to discuss the clinical effects of pantoprazole and octreotide in upper gastrointestinal hemorrhage. Methods: A total of 114 patients with upper gastrointestinal hemorrhage admitted in our hospital from April 2016 to June 2017 were chosen and divided into control and experimental groups by lottery method. The control group (n=57) was treated with pantoprazole and the experimental group (n=57) was treated with pantoprazole+ octreotide. The therapeutic effect, occurrence rate of untoward effects, hemostatic effects at 24 and 72 h, blood-transfusion volume, hemostatic time and rehemorrhage rate at 48 h of the two groups were compared. Results: Compared with the control group, the experimental group exhibited significantly higher total therapeutic and hemostatic effects at 24 h, as well as lower occurrence rate of untoward effects and hemostatic effects at 24 h. Statistically significant differences were observed between the control and experimental groups (P<0.05). The experimental group had greater blood-transfusion volume, shorter hemostatic time and higher rehemorrhage rate at 48 h (P<0.05). Conclusion: The pantoprazole+ octreotide therapy exerted outstanding clinical effects on upper gastrointestinal hemorrhage. This combined therapy can decrease the occurrence rate of untoward effects and bloodtransfusion volume, reduce hemostatic time and prevent recurrent bleeding, thereby being worthy of clinical use and promotion.
Key words: Octreotide, pantoprazole, Upper gastrointestinal hemorrhage